Welcome to our dedicated page for Inhibrx Biosciences news (Ticker: INBX), a resource for investors and traders seeking the latest updates and insights on Inhibrx Biosciences stock.
Inhibrx Biosciences Inc (INBX) is a clinical-stage biopharmaceutical innovator developing targeted therapies for oncology and rare diseases through advanced protein engineering. This dedicated news hub provides investors and industry observers with comprehensive access to official corporate communications and verified developments.
Our curated collection features INBX's latest press releases, regulatory filings, and clinical trial updates. Track progress across therapeutic programs including multivalent biologics and optimized antibody candidates designed through the company's proprietary modular platforms. Stay informed about strategic partnerships, research milestones, and financial disclosures that shape INBX's position in biopharmaceutical innovation.
Key updates include clinical development timelines, intellectual property advancements, and collaborative research initiatives. All content is sourced directly from company filings and authorized statements to ensure reliability. Bookmark this page for streamlined access to INBX's evolving pipeline and corporate announcements, presented with neutral analysis suitable for both institutional and individual investors.
Inhibrx, Inc. (Nasdaq: INBX) announced the initiation of a registration-enabling trial for INBRX-101, a recombinant human AAT-Fc fusion protein targeting emphysema due to alpha-1 antitrypsin deficiency. This trial, named ElevAATe, includes 36 patients receiving doses every three weeks and aims to measure functional AAT concentration over 32 weeks across 35 sites in the U.S., Australia, and New Zealand. Additionally, the FDA lifted the partial clinical hold on INBRX-109, a DR5 agonist. Patient enrollment for INBRX-109 will resume next month, with data anticipated by late 2023 for Phase 1 cohorts and late 2024 for the registration trial data. The company continues to advance its clinical pipeline in oncology and rare diseases.
